Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice

Bull Exp Biol Med. 2021 Aug;171(4):425-430. doi: 10.1007/s10517-021-05242-z. Epub 2021 Sep 20.

Abstract

We studied the possibilities of inhibition of neurodegeneration in MPTP-induced model of Parkinson's disease (PD) in C57Bl/6J mice and transgenic model of early PD stage (5-monthold B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J mice) by autophagy activation through mTOR-dependent and mTOR-independent pathways with rapamycin and trehalose, respectively. Therapy with autophagy inducers in a "postponed" mode (7 days after MPTP intoxication) restored the expression of the dopaminergic neuron marker tyrosine hydroxylase and markedly improved cognitive function in the conditioned passive avoidance response (CPAR; fear memory). The transgenic model also showed an increase in the expression of tyrosine hydroxylase in the nigrostriatal system of the brain. An enhanced therapeutic effect of the combined treatment with the drugs was revealed on the expression of tyrosine hydroxylase, but not in the CPAR test. Thus, activation of both pathways of autophagy regulation in PD models with weakened neuroinflammation can restore the dopaminergic function of neurons and cognitive activity in mice.

Keywords: MPTP; alpha-synuclein; rapamycin; trehalose; tyrosine hydroxylase.

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Adenine / therapeutic use
  • Animals
  • Autophagy / drug effects*
  • Disease Models, Animal
  • MTOR Inhibitors / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neuroinflammatory Diseases / chemically induced
  • Neuroinflammatory Diseases / genetics
  • Neuroinflammatory Diseases / prevention & control*
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / genetics
  • Parkinson Disease / pathology
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy
  • Parkinson Disease, Secondary / pathology
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use
  • Substantia Nigra / drug effects
  • Substantia Nigra / pathology
  • TOR Serine-Threonine Kinases / physiology
  • Trehalose / pharmacology
  • Trehalose / therapeutic use

Substances

  • MTOR Inhibitors
  • Neuroprotective Agents
  • 3-methyladenine
  • Trehalose
  • TOR Serine-Threonine Kinases
  • Adenine
  • Sirolimus